Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52 If approved, Gazyva/Gazyvaro could help children and young adults sustain remission, potentially with a reduced need for steroids to manage their disease1INShore is the first global phase III study of a targeted therapy in this chronic kidney disease commonly diagnosed in early childhood Basel, 28 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today st ...